Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/IFI16_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/IFI16_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/IFI16_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/IFI16_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/IFI16_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/IFI16_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/IFI16_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/IFI16_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/IFI16_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004277111 | Liver | HCC | intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator | 28/7958 | 43/18723 | 2.30e-03 | 1.14e-02 | 28 |
GO:00093146 | Liver | HCC | response to radiation | 223/7958 | 456/18723 | 3.08e-03 | 1.43e-02 | 223 |
GO:001095121 | Liver | HCC | negative regulation of endopeptidase activity | 129/7958 | 252/18723 | 3.17e-03 | 1.47e-02 | 129 |
GO:00450881 | Liver | HCC | regulation of innate immune response | 113/7958 | 218/18723 | 3.27e-03 | 1.50e-02 | 113 |
GO:00458241 | Liver | HCC | negative regulation of innate immune response | 42/7958 | 71/18723 | 3.41e-03 | 1.55e-02 | 42 |
GO:0002218 | Liver | HCC | activation of innate immune response | 32/7958 | 52/18723 | 4.35e-03 | 1.89e-02 | 32 |
GO:0050777 | Liver | HCC | negative regulation of immune response | 101/7958 | 194/18723 | 4.40e-03 | 1.90e-02 | 101 |
GO:200105612 | Liver | HCC | positive regulation of cysteine-type endopeptidase activity | 79/7958 | 148/18723 | 4.82e-03 | 2.03e-02 | 79 |
GO:001046621 | Liver | HCC | negative regulation of peptidase activity | 132/7958 | 262/18723 | 5.82e-03 | 2.42e-02 | 132 |
GO:005110112 | Liver | HCC | regulation of DNA binding | 64/7958 | 118/18723 | 6.60e-03 | 2.68e-02 | 64 |
GO:003022411 | Liver | HCC | monocyte differentiation | 23/7958 | 36/18723 | 7.85e-03 | 3.11e-02 | 23 |
GO:00160328 | Lung | IAC | viral process | 94/2061 | 415/18723 | 5.11e-12 | 4.27e-09 | 94 |
GO:00190588 | Lung | IAC | viral life cycle | 77/2061 | 317/18723 | 1.23e-11 | 4.83e-09 | 77 |
GO:00971938 | Lung | IAC | intrinsic apoptotic signaling pathway | 72/2061 | 288/18723 | 1.36e-11 | 4.83e-09 | 72 |
GO:00723318 | Lung | IAC | signal transduction by p53 class mediator | 47/2061 | 163/18723 | 3.13e-10 | 7.15e-08 | 47 |
GO:00458628 | Lung | IAC | positive regulation of proteolysis | 80/2061 | 372/18723 | 2.62e-09 | 4.21e-07 | 80 |
GO:00723327 | Lung | IAC | intrinsic apoptotic signaling pathway by p53 class mediator | 25/2061 | 76/18723 | 2.76e-07 | 2.18e-05 | 25 |
GO:00714796 | Lung | IAC | cellular response to ionizing radiation | 24/2061 | 72/18723 | 3.60e-07 | 2.57e-05 | 24 |
GO:00105066 | Lung | IAC | regulation of autophagy | 65/2061 | 317/18723 | 4.97e-07 | 3.14e-05 | 65 |
GO:00300998 | Lung | IAC | myeloid cell differentiation | 70/2061 | 381/18723 | 1.12e-05 | 3.45e-04 | 70 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa046213 | Cervix | CC | NOD-like receptor signaling pathway | 41/1267 | 186/8465 | 5.90e-03 | 1.95e-02 | 1.15e-02 | 41 |
hsa0462112 | Cervix | CC | NOD-like receptor signaling pathway | 41/1267 | 186/8465 | 5.90e-03 | 1.95e-02 | 1.15e-02 | 41 |
hsa046219 | Esophagus | HGIN | NOD-like receptor signaling pathway | 45/1383 | 186/8465 | 3.40e-03 | 2.54e-02 | 2.02e-02 | 45 |
hsa0462114 | Esophagus | HGIN | NOD-like receptor signaling pathway | 45/1383 | 186/8465 | 3.40e-03 | 2.54e-02 | 2.02e-02 | 45 |
hsa0462122 | Esophagus | ESCC | NOD-like receptor signaling pathway | 116/4205 | 186/8465 | 2.90e-04 | 1.03e-03 | 5.30e-04 | 116 |
hsa0462132 | Esophagus | ESCC | NOD-like receptor signaling pathway | 116/4205 | 186/8465 | 2.90e-04 | 1.03e-03 | 5.30e-04 | 116 |
hsa046212 | Lung | IAC | NOD-like receptor signaling pathway | 38/1053 | 186/8465 | 1.23e-03 | 8.24e-03 | 5.47e-03 | 38 |
hsa0462111 | Lung | IAC | NOD-like receptor signaling pathway | 38/1053 | 186/8465 | 1.23e-03 | 8.24e-03 | 5.47e-03 | 38 |
hsa046218 | Oral cavity | OSCC | NOD-like receptor signaling pathway | 108/3704 | 186/8465 | 5.13e-05 | 2.07e-04 | 1.05e-04 | 108 |
hsa0462113 | Oral cavity | OSCC | NOD-like receptor signaling pathway | 108/3704 | 186/8465 | 5.13e-05 | 2.07e-04 | 1.05e-04 | 108 |
hsa0462121 | Oral cavity | LP | NOD-like receptor signaling pathway | 73/2418 | 186/8465 | 9.80e-04 | 4.53e-03 | 2.92e-03 | 73 |
hsa0462131 | Oral cavity | LP | NOD-like receptor signaling pathway | 73/2418 | 186/8465 | 9.80e-04 | 4.53e-03 | 2.92e-03 | 73 |
hsa046214 | Oral cavity | EOLP | NOD-like receptor signaling pathway | 48/1218 | 186/8465 | 2.51e-05 | 1.31e-04 | 7.70e-05 | 48 |
hsa046215 | Oral cavity | EOLP | NOD-like receptor signaling pathway | 48/1218 | 186/8465 | 2.51e-05 | 1.31e-04 | 7.70e-05 | 48 |
hsa046216 | Oral cavity | NEOLP | NOD-like receptor signaling pathway | 39/1112 | 186/8465 | 1.79e-03 | 7.91e-03 | 4.98e-03 | 39 |
hsa046217 | Oral cavity | NEOLP | NOD-like receptor signaling pathway | 39/1112 | 186/8465 | 1.79e-03 | 7.91e-03 | 4.98e-03 | 39 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
IFI16 | SNV | Missense_Mutation | | c.1297N>A | p.Pro433Thr | p.P433T | Q16666 | protein_coding | deleterious(0.02) | possibly_damaging(0.88) | TCGA-A2-A0CT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
IFI16 | SNV | Missense_Mutation | | c.649G>A | p.Glu217Lys | p.E217K | Q16666 | protein_coding | tolerated(0.75) | possibly_damaging(0.469) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
IFI16 | SNV | Missense_Mutation | | c.5N>A | p.Gly2Glu | p.G2E | Q16666 | protein_coding | tolerated(1) | benign(0) | TCGA-BH-A0DS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cyclophosphamide | SD |
IFI16 | SNV | Missense_Mutation | novel | c.1190A>G | p.Asn397Ser | p.N397S | Q16666 | protein_coding | tolerated(0.52) | benign(0.192) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
IFI16 | SNV | Missense_Mutation | | c.1673A>T | p.Lys558Met | p.K558M | Q16666 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
IFI16 | SNV | Missense_Mutation | | c.291G>C | p.Lys97Asn | p.K97N | Q16666 | protein_coding | tolerated(0.08) | benign(0.019) | TCGA-E2-A1LB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
IFI16 | SNV | Missense_Mutation | | c.2082N>C | p.Leu694Phe | p.L694F | Q16666 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BI-A0VR-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
IFI16 | SNV | Missense_Mutation | | c.717N>A | p.Phe239Leu | p.F239L | Q16666 | protein_coding | deleterious(0.04) | benign(0.013) | TCGA-EA-A556-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
IFI16 | SNV | Missense_Mutation | | c.2082N>C | p.Leu694Phe | p.L694F | Q16666 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
IFI16 | SNV | Missense_Mutation | | c.1267N>A | p.Glu423Lys | p.E423K | Q16666 | protein_coding | tolerated(0.5) | benign(0.443) | TCGA-IR-A3LH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |